The DNA cytosine deaminase APOBEC3B is a molecular determinant of platinum responsiveness in clear cell ovarian cancer.

CONCLUSIONS: These studies demonstrate that APOBEC3B is overexpressed in a subset of CCOC and, contrary to initial expectations, associated with improved (not worse) clinical outcomes. A likely molecular explanation is that DNA damage caused APOBEC3B sensitizes cells to additional genotoxic stress by cisplatin. Thus, APOBEC3B is a molecular determinant and a candidate predictive biomarker of the therapeutic response to platinum-based chemotherapy. These findings may have broader translational relevance, as APOBEC3B is overexpressed in many different cancer types.
PMID: 32060098 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - February 13, 2020 Category: Cancer & Oncology Authors: Harris RS, Serebrenik AA, Argyris P, Jarvis MC, Brown WL, Bazzaro M, Vogel RI, Erickson BK, Lee SH, Goergen KM, Maurer MJ, Oberg AL, Hou X, Weroha SJ, Kaufmann SH, Huang Y, Heinzen EP Tags: Clin Cancer Res Source Type: research